270 related articles for article (PubMed ID: 10663352)
1. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.
Bouxsein ML; Parker RA; Greenspan SL
Osteoporos Int; 1999; 10(6):505-9. PubMed ID: 10663352
[TBL] [Abstract][Full Text] [Related]
2. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
3. The effect of alendronate on bone mass after distal forearm fracture.
van der Poest Clement E; Patka P; Vandormael K; Haarman H; Lips P
J Bone Miner Res; 2000 Mar; 15(3):586-93. PubMed ID: 10750574
[TBL] [Abstract][Full Text] [Related]
4. Discordance between changes in bone mineral density measured at different skeletal sites in perimenopausal women--implications for assessment of bone loss and response to therapy: The Danish Osteoporosis Prevention Study.
Abrahamsen B; Stilgren LS; Hermann AP; Tofteng CL; Bärenholdt O; Vestergaard P; Brot C; Nielsen SP
J Bone Miner Res; 2001 Jul; 16(7):1212-9. PubMed ID: 11450696
[TBL] [Abstract][Full Text] [Related]
5. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
Greenspan SL; Beck TJ; Resnick NM; Bhattacharya R; Parker RA
J Bone Miner Res; 2005 Sep; 20(9):1525-32. PubMed ID: 16059624
[TBL] [Abstract][Full Text] [Related]
6. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
8. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
9. Alendronate increases bone density and bone strength at the distal radius in postmenopausal women.
Schneider PF; Fischer M; Allolio B; Felsenberg D; Schröder U; Semler J; Ittner JR
J Bone Miner Res; 1999 Aug; 14(8):1387-93. PubMed ID: 10457271
[TBL] [Abstract][Full Text] [Related]
10. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
11. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
12. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
[TBL] [Abstract][Full Text] [Related]
14. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
16. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Ozdemir F; Rodoplu M
Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
[TBL] [Abstract][Full Text] [Related]
17. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
18. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
19. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS
Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170
[TBL] [Abstract][Full Text] [Related]
20. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
Michalská D; Stepan JJ; Basson BR; Pavo I
J Clin Endocrinol Metab; 2006 Mar; 91(3):870-7. PubMed ID: 16352692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
